共查询到15条相似文献,搜索用时 636 毫秒
1.
2.
3.
4.
5.
6.
7.
目的:研究二十二碳六烯酸-磷脂( DHA-PC )对小鼠睡眠的改善作用。方法小鼠随机分为正常对照组、溶剂对照组、DHA鱼油+卵磷脂联合用药(DHA+Lecithin)(60+200)mg/kg(阳性对照)、DHA-PC 50、100、200 mg/kg组,每组10只。正常对照组小鼠自由饮食饮水,溶剂对照组小鼠按0.2 ml/10 g的体积灌胃给予生理盐水, DHA+Lecithin(60+200)mg/kg组和DHA-PC 50、100、200 mg/kg组小鼠均按0.2 ml/10 g的体积灌胃给药,1次/d,连续30 d。通过测定小鼠直接睡眠时间、戊巴比妥钠诱导睡眠时间、阈下剂量睡眠发生率及巴比妥钠诱导睡眠潜伏时间,观察DHA-PC对小鼠睡眠的作用。结果3种剂量的DHA-PC对小鼠体质量均无影响。直接睡眠实验结果表明,3种剂量的DHA-PC对小鼠直接睡眠无影响。戊巴比妥钠诱导睡眠实验结果表明, DHA-PC 50、100、200 mg/kg组小鼠戊巴比妥钠诱导睡眠时间分别为(56.2±13.7),(57.9±25.4)及(64.1±18.4)min,明显高于溶剂对照组(32.9±10.8) min ( P <0.05);DHA +Lecithin (60+200) mg/kg 组小鼠的戊巴比妥钠睡眠时间为(38.6±11.7)min,高于溶剂对照组小鼠(32.9±10.8)min,但无明显差异;DHA-PC 200mg/kg组明显高于DHA+Lecithin (60+200)mg/kg组(P<0.05)。协同戊巴比妥钠阈下剂量催眠实验结果表明,DHA-PC 200 mg/kg组小鼠协同戊巴比妥钠阈下剂量催眠入睡率(70%)明显高于溶剂对照组(10%)(P<0.05);DHA+Lecithin (60+200) mg/kg组小鼠协同戊巴比妥钠阈下剂量催眠入睡率(60%)明显高于溶剂对照组(10%)( P<0.05)。巴比妥钠诱导睡眠潜伏期实验结果表明,DHA-PC 200 mg/kg和DHA+Lecithin (60+200) mg/kg组小鼠巴比妥钠诱导睡眠潜伏时间分别为(22.9±4.1)和(19.5±2.7)min,明显低于溶剂对照组(31.3±6.9)min(P<0.01),且DHA+Leci-thin(60+200)mg/kg组小鼠巴比妥钠诱导睡眠潜伏时间为(19.5±2.7)min,明显低于DHA-PC 50和100 mg/kg组,二者分别为(27.3±2.4)和(26.9±4.2)min。结论 DHA-PC具有改善小鼠睡眠的作用。 相似文献
8.
9.
10.
目的探究西咪替丁(CMTD)对局部分割照射小鼠的治疗作用。方法雄性C57BL/6小鼠30只,随机单位组设计分为对照组、单纯照射组和照射给药组(CMTD,100 mg/kg),每组10只;采用X射线局部分割照射小鼠右胸腔,8 Gy/d照射,连续3 d,累积照射剂量为24 Gy,剂量率为0.883 Gy/min。照射后连续7 d给予照射给药组小鼠灌胃CMTD(100 mg·kg^-1·d^-1),对照组和单纯照射组给予生理盐水。照射后第7天检测小鼠体重、脏器指数、脾脏T淋巴细胞亚群、B淋巴细胞亚群、NK细胞亚群变化以及脾脏组织病理学改变。结果分割照射对小鼠体重影响不大,但可诱发远端效应,使脾脏脏器指数降低为(0.369±0.011),与对照组的(0.396±0.022)比较,差异有统计学意义(t=2.978,P<0.05);改变脾脏病理结构,脾脏CD3+、CD4+、CD8+、CD3+CD4+、CD3+CD8+淋巴细胞比例显著降低(t=5.754、3.570、4.442、5.281、4.570,P<0.05)。而照射给药组小鼠体重恢复明显,脾脏组织损伤缓解,脾脏淋巴细胞亚群比例恢复,CD3+、CD3+CD4+、CD3+CD8+淋巴细胞显著升高(t=3.523、2.706、2.520,P<0.05),但仍低于正常水平。结论CMTD可有效改善X射线分割照射对小鼠脾脏的损伤,提高照后小鼠的免疫功能,可作为潜在的抗辐射治疗药物。 相似文献
11.
12.
Influence of the Leaf Extract of Mentha arvensis Linn. (Mint) on the Survival of Mice Exposed to Different Doses of Gamma Radiation 总被引:1,自引:0,他引:1
BACKGROUND: The aim of the present study was to evaluate the radioprotective effect of Mentha arvensis (mint) on the survival of mice exposed to various doses of whole-body gamma radiation. MATERIAL AND METHODS: The radioprotective effect of various doses (0, 2.5, 5, 10, 20, 40 and 80 mg/kg body weight) of chloroform extract of mint (Mentha arvensis Linn.) was studied in mice exposed to 10 Gy gamma radiation. RESULTS: The 10 mg/kg of mint extract was found to afford best protection as evidenced by the highest number of survivors in this group at 30 days post-irradiation, and further experiments were carried out using this dose of mint extract. The mice treated with 10 mg/kg body weight mint extract or oil were exposed to 6, 7, 8, 9 and 10 Gy of gamma radiation and observed for the induction of radiation-sickness and mortality up to 30 days post-irradiation. The mint extract pretreatment was found to reduce the severity of symptoms of radiation sickness and mortality at all exposure doses and a significant increase in the animal survival was observed when compared with the oil + irradiation group. All of the animals that were treated with 10 mg/kg mint extract and then exposed to 7 Gy irradiation were protected against the radiation-induced mortality when compared with the concurrent oil + irradiation group, in which 20% animals died by 30 days post-irradiation. The mint extract treatment protected the mice against the gastrointestinal death as well as bone marrow deaths. The DRF was found to be 1.2. The drug was non-toxic up to a dose of 1,000 mg/kg body weight, the highest drug dose that could be tested for acute toxicity. CONCLUSION: From our study it is clear that mint extract provides protection against the radiation-induced sickness and mortality and the optimum protective dose of 10 mg/kg is safe from the point of drug-induced toxicity. 相似文献
13.
目的探讨全反式维甲酸(ATRA)和曲古抑素(TSA)对人甲状腺滤泡状癌细胞株(FTC-133)和荷人甲状腺滤泡状癌裸鼠(NMB—hFTC)肿瘤模型摄碘能力的影响。方法不同量ATRA、TSA诱导VFC-133细胞:ARTA 1.0×10^-6mo/L(A低组)、1.0×10^-4mol/L(A高组)、TSA1.65×10^-7mol/L(T组)、A低+T组、A高+T组和无水乙醇(对照组),96h后行HE染色,测定FTC-133细胞摄碘率;制备NMB—hFTC,成瘤后分组:ATRA组(2mg/kg灌胃)、TSA组(10mg/kg腹腔注射)、联合组(ATRA+TSA,用量同前)、对照组(生理盐水灌胃+腹腔注射,均为10ml/kg),剂量均按鼠体质量给予。给药22d后,腹腔注射37MBq ^131I,分别于注射后4,6,12和24h行γ显像,测定体内生物分布;显像后取肿瘤组织行HE染色观察细胞形态。实验结果采用SPSS13.0软件进行单因素方差分析。结果FTC-133细胞摄碘率A低+T组、A高+T组分别为(23885±616.0)和(13849±728.2)计数·min^-1·10^-6细胞,其他各组在(985±84.2)~(17600±782.7)计数·min^-1·10^-6细胞范围内,各组间比较差异有统计学意义(F=600.879,P〈0.001)。^131I注射后6,12和24h联合组裸鼠种植瘤%ID/g分别为6.17±0.46,9.34±0.61,11.19±0.98,其余各组保持在(1.97±0.34)~(5.14±0.65)之间;肿瘤质量各组间比较差异有统计学意义(F=3.723,P〈0.05)。结论ATRA联合TSA,可增强FTC-133细胞和NMB—hFTC病灶的分化、摄碘能力,达到增强^131I杀死甲状腺癌病灶的协同作用。 相似文献
14.
目的 观察血小板源性生长因子-AA(PDGF-AA)处理能否增加真皮多能干细胞(dMSCs)向全身照射(TBI)大鼠骨髓的分布.方法 分离雄性大鼠dMSCs,向第3代dMSCs中加入10μg/L PDGF-AA,继续培养2 h后,Western blot检测dMSCs中tenascin-C的表达,Transwell小室观察dMSCs的迁移能力,并收集细胞静脉移植到雌性全身照射大鼠体内,伤后2周采用针对Y染色体的实时定量PCR法检测骨髓中dMSCs含量.以未处理的dMSCs作为对照.结果 与未处理的dMSCs相比,PDGF-AA处理可上调dMSCs中tenascin-C的表达,在骨髓提取液的趋化下迁移到Transwell小室下层的细胞多,移植后分布到骨髓的dMSCs数量为(1.79±0.13)×105个,明显高于未处理的(1.24±0.09)×105个(t=8.833,P<0.01).结论 移植前用PDGF-AA处理dMSCs可增强其迁移能力,并可增加其向全身照射大鼠骨髓的分布.Abstract: Objective To observe whether dermal multipotent stem cells (dMSCs) treated with platelet-derived growth factor-AA ( PDGF-AA )could distribute more frequently to the bone marrow in rats of total body irradiation (TBI).Methods Male dMSCs were isolated and 10 μg/L PDGF-AA was added to the culture medium and further cultured for 2 h.Then the expression of tenascin-C were examined by Western blot, and the migration ability of dMSCs was assessed in transwell chamber.The pre-treated dMSCs were transplanted by tail vein injection into female rats administered with total body irradiation, and 2 weeks after transplantation, real-time PCR was employed to measure the amount of dMSCs in bone marrow.Non-treated dMSCs served as control.Results PDGF-AA treatment increased the expression of tenascin-C in dMSCs, made (1.79 ± 0.13) × 105 cells migrate to the lower chamber under the effect of bone marrow extract, and distributed to bone marrow in TBI rats, significantly more than ( 1.24 ± 0.09) ×105 in non-treated dMSCs (t = 8.833, P < 0.0l ).Conclusions PDGF-AA treatment could enhance the migration ability of dMSCs and increase the amount of dMSCs in bone marrow of TBI rats after transplantation. 相似文献
15.
目的 比较不同血液净化方式对肾性骨病相关指标的影响.方法 选取在我院血液净化中心行维持性血液透析(maintenance hemodialysis,MHD)6个月以上均符合肾性骨病诊断的患者64例,随机分为4组,即低通量血液透析(HD)、高通量血液透析(HFHD)、血液透析+血液透析滤过(HD+ HDF)(1次/周)及血液透析+血液灌流(HD+ HP)(1次/周),每组16例,比较各组治疗前及治疗24周后血钙(Ca)、血磷(P)、甲状旁腺激素(PTH)、碱性磷酸酶(ALP)及β2-微球蛋白(β2-MG),并计算钙磷乘积(Ca×P).结果 HFHD组、HD+ HDF组及HD+ HP组治疗后与治疗前相比血P、PTH、ALP、β2-MG、Ca×P均显著下降,差异有统计学意义(P<0.05);HD+ HDF组治疗后清除血P(1.91±0.19) mmol/L、β2-MG(11.32 ±2.61)mg/L及PTH(347.21±152.05) pg/ml优于HFHD组(1.98 ±0.14) mmol/L、β2-MG(17.09±5.60) mg/L及PTH(471.98±123.02) pg/ml,HD+ HP组治疗后清除血P(1.92±0.09) mmol/L、β2-MG(12.62±3.34) mg/L及PTH(337.96±142.80) pg/ml也优于HFHD组,差异有统计学意义(P<0.05),HD+ HDF组与HD+ HP组相比差异无统计学意义;HD组治疗前后血P、Ca×P、PTH、β2-MG水平差异无统计学意义.4组治疗前后血钙水平差异无统计学意义.结论 HFHD组、HD+ HDF组、HD+HP组在清除血 P、PTH及β2-MG 上优于HD组,尤其HD+ HDF组、HD+HP组更优. 相似文献